Nivolumab
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Jun 2, 2017 → Mar 14, 2022
NCT ID
NCT03090737About Nivolumab
Nivolumab is a phase 2 stage product being developed by Ono Pharmaceutical for Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03090737. Target conditions include Non-Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03987815 | Phase 2 | UNKNOWN |
| NCT03383458 | Phase 3 | Active |
| NCT03090737 | Phase 2 | Completed |
| NCT02857426 | Phase 2 | Completed |
| NCT02743494 | Phase 3 | Completed |
| NCT02632409 | Phase 3 | Active |
| NCT02387996 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Small Cell Lung Cancer